AstraZeneca gets an additional FDA approval for its diabetes drug

The Food and Drug Administration approved AstraZeneca's drug Farxiga as a treatment for reducing the risk of hospitalizations for heart failure in adults with type-2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors.

Farxiga, developed by AstraZeneca (NYSE: AZN) in a partnership with Bristol-Myers Squibb, already had FDA approval as a therapy along with diet and exercise to lower blood sugar in adults with type 2 diabetes. The drug generated sales of more than…

Source: bizjournals.com Health Care:Pharmaceuticals headlines - October 21, 2019 Category: Pharmaceuticals Authors: John George Source Type: news